Trials / Not Yet Recruiting
Not Yet RecruitingNCT06897527
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)
Phase 4, Open Label, Non-comparative, Interventional, Multicenter Study to Evaluate the Safety of Dostarlimab in Adult Patients in India With Mismatch Repair Deficient (dMMR)/Microsatellite Instability-high (MSI-H) Recurrent or Advanced Endometrial Cancer (EC) That Has Progressed on or Following Prior Treatment With a Platinum-containing Regimen
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dostarlimab | Dostarlimab will be administered. |
Timeline
- Start date
- 2025-07-15
- Primary completion
- 2027-01-13
- Completion
- 2027-01-13
- First posted
- 2025-03-27
- Last updated
- 2025-07-08
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06897527. Inclusion in this directory is not an endorsement.